Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.33 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.33 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
| ▸ | KLK1 | P06870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9930160 | 0.90 | KCNJ1 (0.36) | KCNH2 | |
| SCHEMBL9930501 | 0.87 | KCNH2 (0.36) | KCNH2AOC3 | |
| SCHEMBL9930295 | 0.85 | KCNH2 (0.34) | KCNH2AOC3 | |
| SCHEMBL14069204 | 0.85 | KCNH2 (0.38) | KCNH2EGLN2TET2OGFOD1TET1 | |
| SCHEMBL9930200 | 0.85 | KCNH2 (0.53) | KCNH2EGLN2TET2OGFOD1TET1 | |
| SCHEMBL14069901 | 0.85 | KCNH2 (0.53) | KCNH2EGLN2TET2OGFOD1TET1 | |
| SCHEMBL9930491 | 0.84 | KCNH2 (0.38) | KCNH2AOC3 | |
| SCHEMBL9968645 | 0.83 | KCNH2 (0.44) | KCNH2EGLN2TET2OGFOD1TET1 | |
| SCHEMBL14069203 | 0.83 | KCNH2 (0.37) | KCNH2EGLN2CHRM1 | |
| SCHEMBL9964774 | 0.83 | KCNH2 (0.37) | KCNH2EGLN2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | NISCH, NOD1, NQO1 | KCNH2 1295/4885EGLN2 258/4885TET2 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.